Sanofi forecast moderate earnings growth this year, with the French drugmaker saying demand for its asthma and eczema drug Dupixent would be partly offset by competition for its multiple sclerosis pill Aubagio https://t.co/bGPvfi9d9v pic.twitter.com/j5KmsDE0O2— Reuters (@Reuters) February 3, 2023
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


